ReviewFrontiers in cellular and infection microbiology2025
A one health perspective on multidrug-resistant bacterial infections: integrated approaches for surveillance, policy and innovation.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Genomic insights into multidrug-resistant bacteria: Emergence ofVirulence · 2026Article
- Integrated Molecular Docking and Molecular Dynamics Approaches Reveal Potential Antimicrobial Metabolites from Echinoderms,Biology · 2026Article
- The Global Impact of Bacterial Antimicrobial Resistance: Addressing Gaps and Future Strategies.Public health challenges · 2026Article
- Efficacy and Safety of Different Colistin Administration Routes for Nosocomial Pneumonia Caused by Carbapenem-Resistant Organisms: A Single Centre, Open Label, Prospective Cohort Study.Drug design, development and therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) bacterial infections represent a growing global health emergency, driven by interconnected human, animal, and environmental factors. This review adopts a One Health perspective to explore the transmission dynamics, operational integration, and innovative responses to antimicrobial resistance (AMR). Case studies from China, India, Nigeria, Thailand, and Brazil underscore the effectiveness of regulatory reforms, surveillance networks, and public engagement campaigns. Notably, Artificial Intelligence (AI) is transforming MDR management through real-time diagnostics and resistance prediction, though ethical concerns and infrastructure deficits in Low- and Middle-Income Countries (LMICs) remain barriers. Community-led initiatives, gender-sensitive education, and policy reforms are vital to curbing misuse and closing equity gaps. Despite successes, challenges such as fragmented governance, underfunded labs, and limited longitudinal research persist. A proactive, integrated One Health approach-linking clinical, environmental, and policy actions-is essential for reducing MDR burden. Investment in intersectoral surveillance, equitable AI deployment, and community empowerment is imperative for safeguarding antibiotics and ensuring global health resilience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.